3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
4
Stomach Neoplasms
2
Melanoma
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Malignant Solid Tumour
1
Liver Neoplasms
1
Fibrosis
1
Colorectal Neoplasms
1
Colorectal Cancer Metastatic
1
Carcinoma
1
Interventions
Gemcitabine
11
pembrolizumab
10
Oxaliplatin
7
Nivolumab
7
Irinotecan
7
Fluorouracil
7
Capecitabine
7
durvalumab
6
Sorafenib
6
Leucovorin
6
Cyclophosphamide
6
Paclitaxel
5
Ipilimumab
5
tislelizumab
3
poly ICLC
3
lenvatinib
3
fludarabine
3
Sunitinib
3
Radiotherapy
3
Cisplatin
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
seocalcitol
2
selinexor
2
pemigatinib
2
futuximab
2
fludarabine phosphate
2
donafenib
2
cemiplimab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
ARQ 197
×
Gastrointestinal
×
Clear all
NCT01755767
2021-04-06
METIV-HCC
Daiichi Sankyo
Phase 3
Completed
383 enrolled
17 charts